Abnormality of Gait as a Predictor of Non-Alzheimer's Dementia
NEJM 347:1761-1768, Verghese,J.,et al, 2002
Driving Safety in Parkinson's Disease
Neurol 59:1787-1788, Zesiewicz,T.A.,et al, 2002
Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002
Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease
JAMA 287:455-463,509, Hobson,D.E.,et al, 2002
Practice Parameter: Initiation of Treatment for Parkinson's Disease: An Evidence-based Review
Neurol 58:11-17, Miyasaki,J.M.,et al, 2002
Diffusion-weighted MRI Differentiates the Parkinson Variant of Multiple System Atrophy from PD
Neurol 58:575-580, Schocke,M.F.H.,et al, 2002
Clinicopath Conf, Primary Lymphoma of CNS
NEJM 346:1009-1015, Case 10-2002, 2002
Clinicopath Conf., Cerebral Venous Thrombosis, Resulting in Hemorrhagic Infarction of the Posterior Left Temporal Lobe
NEJM 346:1651-1658, Case 16-2002, 2002
Donepezil for Cognitive Impairment in Parkinson's Disease: A Randomised Controlled Study
JNNP 72:708-712, Aarsland,D.,et al, 2002
Incidence and Prediction of Falls in Parkinson's Disease: A Prospecitve Multidisciplinary Study
JNNP 72:721-725, Wood,B.H.,et al, 2002
Therapies for Movement Disorders
Arch Neurol 59:699-702, Goetz,C.G &Hinson,V.K., 2002
Friedreich Ataxia
Arch Neurol 59:743-747, Lynch,D.R.,et al, 2002
Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS
Neurol 58:1404-1407,1323, Killestein,J.,et al, 2002
Treatment Interventions for Parkinson's Disease: An Evidence Based Assessment
Lancet 359:1589-1598, Rascol,O.,et al, 2002
Impact of Sustained Deprenyl (Selegiline) in Levodopa-Treated Parkinson's Disease: A Randomized Placebo-Controlled Extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial
Ann Nuerol 51:604-612, Shoulson,I.,et al, 2002
Cholinergic Vesicular Transporters in Progressive Supranuclesar Palsy
Neurol 58:1013-1018,997, Suzuki,M.,et al, 2002
Botulinum Toxin for Cricopharyngeal Dysfunction in Parkinson's Disease
NEJM 346:1174-1175, Restivo,D.A.,et al, 2002
HIV-Related Movement Disorders, Epidemiology, Pathogenesis and Management
CNS Drugs 16:663-668, Cardoso,F., 2002
Stem-Cell Research: Drawing the Line
Lancet 358:163,217, Greenberg,D.S., 2001
Subclinical Dopaminergic Dysfunction in Asymptomatic Parkinson's Disease Patients' Relatives with a Decreased Sense of Smell
Ann Neurol 50:34-41, Berendse,H.W.,et al, 2001
Reversible Parkinsonism and MRI Diffusion Abnormalities in Cortical Venous Thrombosis
Neurol 57:364-366, Jenkins,M.,et al, 2001
Mild Guillain-Barre Syndrome
Arch Neurol 58:1098-1101, Green,D.M. &Ropper,A.H., 2001
Effects of Bilateral Subthalamic Nucleus Stimulation on Parkinsonian Gait
Neurol 57:144-146, Stolze,H.,et al, 2001
Open-Label Dose-Titration Safety and Efficacy Study of Tizanidine Hydrocholoride in the Treatment of Spasticity Associated With Chronic Stroke
Stroke 32:1841-1846, Gelber,D.A.,et al, 2001
Effects of Bilateral Subthalamic Stimulation on Cognitive Function in Parkinson Disease
Arch Neurol 58:1223-1227,1205, Alegret,M.,et al, 2001
Welding-Related Parkinsonism
Neurol 56:8-13,4, Racette,B.A.,et al, 2001
Cerebellar Ataxia With Anti-Glutamic Acid Decarboxylase Antibodies
Arch Neurol 58:225-230, Honorat,J.,et al, 2001
SCA-12: Tremor with Cerebellar and Cortical Atrophy is Associated with a CAG Repeat Expansion
Neruol 56:299-303,287, O'Hearn,E.,et al, 2001
Headache and CNS White Matter Abnormalities Associated with Gluten Sensitivity
Neurol 56:385-388, Hadjivassiliou,M.,et al, 2001
Involuntary Movements After Anterior Cerebral Artery Territory Infarction
Stroke 32:258-261, Kim,J.S., 2001
Parkinsonism as the Presenting Manifestation of HIV Infection: Improvement on HAART
Neurol 56:278-279, Hersh,B.P.,et al, 2001
Functional Correlates of Pallidal Stimulation for Parkinson's Disease
Ann Neurol 49:155-164,142, Fukuda,M.,et al, 2001
Thalamic Deep Brain Stimulation
Arch Neurol 58:218-222, Ondo,W.,et al, 2001
Safety and Efficacy of Pallidal or Subthalamic Nucleus Stimulation in Advanced PD
Neurol 56:548-551, Volkmann,J.,et al, 2001
Deep Brain Stimulation of the Subthalamic Nucleus: Clinical Effectiveness and Safety
Neurol 56:552-554, Lopiano,L.,et al, 2001
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
NEJM 344:710-719,763, Freed,C.R.,et al, 2001
Confusion After Antibiotics
Lancet 357:1410, Gavazzi,C.,et al, 2001
Gluten Sensitivity in Sporadic and Hereditary Cerebellar Ataxia
Ann Neurol 49:540-543, Bushara,K.O.,et al, 2001
Recurrent Reversible Paraplegia
Lancet 357:1092, Haran,M. & Ni,S., 2001
Dysarthria in Acute Ischemic Stroke
Neurol 56:1021-1027, Urban,P.P.,et al, 2001
MR Imaging Findings After Stereotactic Radiosurgery Using the Gamma Knife
AJR 176:1589-1595, Friedman,D.P.,et al, 2001
DBS and Diathermy Interaction Induces Severe CNS Damage
Neurol 56:1384-1386, Nutt,J.G.,et al, 2001
Deep Brain Stimulation in the Treatment of Parkinson's Disease,A Cost-Effectiveness Analysis
Neurol 57:663-671, Tomaszewski,K.J.&Holloway,R.G., 2001
Comtan (Entacapone) The Treatment of Parkinson's Disease, Questions & Answers
APDA Ed Suppl #15, Watts,R.L., 2001
A randomized,Double-blind,Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events
Arch Neurol 58:1385-1392, Dewey,R.B.,et al, 2001
Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson's Disease
NEJM 345:956-963, The Deep-Brain Stimulation for Parkinson's Disease, 2001
Improved Accuracy of Clinical Diagnosis of Lewy Body Parkinson's Disease
Neurol 57:1497-1499, Hughes,A.J.,et al, 2001
Daytime Sleepiness and Other Sleep Disorders in Parkinson's Disease
Neurol 57:1392-1396, Ondo,W.G.,et al, 2001
Hallucinations in Parkinson's Disease
Lancet 358:1031-1032, Korczyn,A.D., 2001
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001